Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies-Reference-Cited by-同舟云学术

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

Published:2008-08 Issue:8 Volume:58 Page:2443-2452
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Hoffman Hal M.,Throne Martin L.,Amar N. J.,Sebai Mohamed,Kivitz Alan J.,Kavanaugh Arthur,Weinstein Steven P.,Belomestnov Pavel,Yancopoulos George D.,Stahl Neil,Mellis Scott J.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference25 articles.

1. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome;Hoffman;Nat Genet,2001

2. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes;Feldmann;Am J Hum Genet,2002

3. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model;Aksentijevich;Arthritis Rheum,2007

4. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations;Hull;Curr Opin Rheumatol,2003

5. Unraveling the NALP-3/IL-1β inflammasome: a big lesson from a small mutation;Dinarello;Immunity,2004

Cited by 520 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Utility of Rilonacept for the Treatment of Recurrent Pericarditis: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2024-09

2. Mechanisms of Senescence and Anti-Senescence Strategies in the Skin;Biology;2024-08-23

3. Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms;Journal of Bone Oncology;2024-08

4. Newer Immunosuppressants for Rheumatologic Disease;Rheumatic Disease Clinics of North America;2024-08

5. Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS;Annals of the Rheumatic Diseases;2024-04-23